If academic discoveries turn out to be wrong, one drug company wants its money back.
That’s the tough-minded proposal floated today by the chief medical officer of Merck & Co., one of the world’s 10 largest drug companies, as a way to fix the “reproducibility crisis,” or how many, if not most, published scientific reports turn out to be incorrect.
May 8-11, 2016 – Grand Hyatt Washington DC in Washington, DC
Health Datapalooza is the gathering place for people and organizations creating knowledge from data and pioneering innovations that drive health policy and practice, and generate market value. Conceived as part of a public/private movement to liberate and use health data, the Datapalooza continues its tradition of engaging patient and consumer voices, and bringing national and international leaders from the C-levels of business and government together for engaging discussions.
We’re excited to invite you to join us for the 2016 Health Datapalooza – the meeting that brings data to life in ways that matter in health and health care. This year’s meeting finds us even closer to the reality of using data, analytics, and technology to re-define how we deliver and pay for health care. Come hear how data sharing, use, and transparency fuels innovative applications and business models that are building momentum towards a vibrant health information economy that drives high value health care.
Presented by the Tech Council of Maryland, Bio+Tech16 reflects the changing landscape where life sciences and technology converge by bringing together more than 500 professionals in both fields so that they may meet and forge new partnerships that will lead to great new discoveries. Bio+Tech16 is the first event of its kind in the Mid-Atlantic region that brings together the life science and technology sectors to meet and leverage the talents of the other to grow their organizations and their industry.
A simple blood test to detect early signs of cancer. A noninvasive way to screen pregnancies for common genetic conditions. An app store for your genetic information. Illumina, a San Diego-based gene-sequencing hardware and software behemoth with a market capitalization of $22 billion, is working on all these initiatives—and more.
University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating–and optimizing–this tech transfer process is therefore critical to the health of the biotech sector.
Incubators aren’t just for startups and entrepreneurs with a business idea. A new film incubator at Johns Hopkins University will look to cultivate new ideas for producing films and give a voice to local filmmakers and visual artists. The program, called the Bold Voices, New Paradigms Incubator, is part of the Saul Zaentz Innovation Fund in Film and Media Studies, which was launched by a $1 million grant from the Saul Zaentz Charitable Foundation.
Hello Tomorrow is a global non-profit headquartered in Paris that aims to accelerate science & tech innovation by empowering startups with cash prizes and connections with investors and industrials. It was created in 2011 by Xavier Duportet & Arnaud de la Tour. Hello Tomorrow is supported by the French public and private sectors, but remains an independent organization governed by entrepreneurs.
Novartis (NOVN.S) is discussing options with banks for selling its near $14 billion (9.7 billion pounds) stake in rival Roche (ROG.S), potentially providing cash for new deals, though a sale is not imminent, according to two people familiar with the situation.
Merely 5 percent of healthcare organizations worldwide are “operating at the highest level of digital health innovation proficiency and expertise,” according to a report from digital health consulting firm Enspektos. That means the vast majority have yet to scale and share their innovations, even within their own walls.
Dr. Jay Bradner, a decorated cancer researcher from the Dana-Farber Cancer Institute, turned heads last year when he accepted a top job at Novartis, one of the world’s largest drug makers. Academics jump to industry all the time, but Bradner made his name with a move pharma almost never makes: When he discovered a potentially cancer-fighting molecule, he just gave it away.
